Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
ATMARINOMED6
Tue, 27.12.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech receives US Patent approval for the Marinosolv® technology and invests in a series of new patents US patent significantly extends geographical protection and complements patents in Europe and Greater China Comprehensive patent protection to drive growth for pipeline products and Solv4U technology partnerships Marinomed to resum [ … ]
Technical analysis
To the publication
Tue, 27.12.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech receives US Patent approval for the Marinosolv® technology and invests in a series of new patents US patent significantly extends geographical protection and complements patents in Europe and Greater China Comprehensive patent protection to drive growth for pipeline products and Solv4U technology partnerships Marinomed to resum [ … ]
Technical analysis
To the publication
Mon, 21.11.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and significant business development progress Revenues for the first 9 months 2022 (9M) increased by 24% to € 7.1 m (9M 2021: € 5.7 m) Operating result (EBIT) for the first nine months further improved by 26% to € ‑3.8 m (9M 2021: €-5.2 m) Partnerships are progressing  [ … ]
Technical analysis
To the publication
Mon, 21.11.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG reports increase in revenues for the first 9 months 2022 and significant business development progress Revenues for the first 9 months 2022 (9M) increased by 24% to € 7.1 m (9M 2021: € 5.7 m) Operating result (EBIT) for the first nine months further improved by 26% to € ‑3.8 m (9M 2021: €-5.2 m) Partnerships are progressing  [ … ]
Technical analysis
To the publication
Thu, 20.10.2022       Marinomed Biotech AG
ATMARINOMED6

First successful year on the market for Marinomed’s Solv4U technology partnerships Several feasibility studies completed; follow-on formulation and optimization stages due to start Compounds from more than ten substance classes successfully solubilized Marinomed will be attending BioEurope in Leipzig, Germany from 24-24 October 2022 and CPHI in  [ … ]
Technical analysis
To the publication
Thu, 20.10.2022       Marinomed Biotech AG
ATMARINOMED6

First successful year on the market for Marinomed’s Solv4U technology partnerships Several feasibility studies completed; follow-on formulation and optimization stages due to start Compounds from more than ten substance classes successfully solubilized Marinomed will be attending BioEurope in Leipzig, Germany from 24-24 October 2022 and CPHI in  [ … ]
Technical analysis
To the publication
Tue, 13.09.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed to attend several upcoming investor and industry conferences Korneuburg, Austria, 13 September 2022 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, today announced that they will be attending several upcoming investor and industry conferences where they will be available f [ … ]
Technical analysis
To the publication
Tue, 13.09.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed to attend several upcoming investor and industry conferences Korneuburg, Austria, 13 September 2022 – Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, today announced that they will be attending several upcoming investor and industry conferences where they will be available f [ … ]
Technical analysis
To the publication
Thu, 25.08.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG continues its growth path and reports strong financials in H1 2022 Record H1 revenues; increase by 52 % compared to H1 2021 Operating Result (EBIT) for the first half year improved to € -2.5 m Carragelose sales remain high; important new partnerships in the US and Asia First Solv4U partnerships are advancing to follow-on pr [ … ]
Technical analysis
To the publication
Thu, 25.08.2022       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG continues its growth path and reports strong financials in H1 2022 Record H1 revenues; increase by 52 % compared to H1 2021 Operating Result (EBIT) for the first half year improved to € -2.5 m Carragelose sales remain high; important new partnerships in the US and Asia First Solv4U partnerships are advancing to follow-on pr [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 18.10.2024, Calendar Week 42, 292nd day of the year, 74 days remaining until EoY.